(Q38025738)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Olaparib, PARP1 inhibitor in ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Maria Luisa Gasparri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Innocenza Palaia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Terenzio Boni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Filippo Bellati

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Ludovica Imperiale

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sandro Pignata

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Pierluigi Benedetti Panici

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

English

0 references

publication date

13 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

1575-1584

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

New therapies for ovarian cancer: cytotoxics and molecularly targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

"Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

The role of targeted therapy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

New colorimetric cytotoxicity assay for anticancer-drug screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707189

10.1517/13543784.2012.707189

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788971%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference